Company intelligence / Profile preview

Scout

Santa Clara, California, United States

Ownership: Private
Employees: ~12
Development stage: Other

Overview

Scout has developed an FDA-authorized molecular diagnostic platform (initially for SARS-CoV-2) that delivers lab-level accuracy at the point of care and is expanding its menu to respiratory, sexual, women’s health, and chronic disease testing; an OTC COVID-19 test is under FDA review and STI tests are in proof-of-concept development with CARB-X support[2][4].

Therapeutic areas: OncologyWomen's HealthInfectious Diseases
Modalities: DeviceMolecular diagnosticsNon-pharmacological therapy
Industry: Molecular Diagnostics

Partnerships

U.S. National Institutes of Health (NIH) non-dilutive funding[2][5].CARB-X award for STI Scout point-of-care/at-home STI testing[4].Support from institutions such as Johns Hopkins University and Emory University[5].

Beyond the preview

Go deeper on Scout.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scout.

Explore the full profile